Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Dharminder Chauhan, Ajita V. Singh, Monette Aujay, Christopher J. Kirk, Madhavi Bandi, Bryan Ciccarelli, Noopur Raje, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (23): 4906–4915.

https://doi.org/10.1182/blood-2010-04-276626

Published: 2010

Journal Articles

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia

Aldo M. Roccaro, Antonio Sacco, Monette Aujay, Hai T. Ngo, Abdel Kareem Azab, Feda Azab, Phong Quang, Patricia Maiso, Judith Runnels, Kenneth C. Anderson, Susan Demo, Irene M. Ghobrial

Blood (2010) 115 (20): 4051–4060.

https://doi.org/10.1182/blood-2009-09-243402

Published: 2010

Includes: Supplemental data

Journal Articles

Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.

Aldo M. Roccaro, MD, PhD, Antonio Sacco, Monette Aujay, Hai Ngo, Feda Azab, BPharm, Abdel Kareem Azab, PhD, BPharm, Molly Melhem, Judith M. Runnels, PhD, Phong Quang, Susan Demo, PhD, Irene Ghobrial, M.D.

Blood (2009) 114 (22): 4911.

https://doi.org/10.1182/blood.V114.22.4911.4911

Published: 2009

Journal Articles

Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.

Antonio Sacco, Aldo M. Roccaro, MD, PhD, Monette Aujay, PhD, Hai Ngo, Feda Azab, BPharm, Abdel Kareem Azab, Bpharm, PhD, Molly R Melhem, Judith M. Runnels, PhD, Phong Quang, Susan Demo, PhD, Irene Ghobrial, M.D.

Blood (2009) 114 (22): 4916.

https://doi.org/10.1182/blood.V114.22.4916.4916

Published: 2009

Journal Articles

PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.

Ajita V. Singh, Madhavi Bandi, Monette Aujay, Susan Demo, PhD, Teru Hideshima, Nikhil C. Munshi, Paul G. Richardson, Dharminder Chauhan, Ph.D, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 612.

https://doi.org/10.1182/blood.V114.22.612.612

Published: 2009

Journal Articles

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Rediet Zewdu, B.S., Francesco Parlati, PhD, Monette Aujay, B.S., Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 2854.

https://doi.org/10.1182/blood.V114.22.2854.2854

Published: 2009

Journal Articles

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Francesco Parlati, Susan J. Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, James B. Lorens, David R. Micklem, Paulina Ruurs, Catherine Sylvain, Yan Lu, Kevin D. Shenk, Mark K. Bennett

Blood (2009) 114 (16): 3439–3447.

https://doi.org/10.1182/blood-2009-05-223677

Published: 2009

Includes: Supplemental data

Journal Articles

The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration

Christopher J Kirk, Jing Jiang, Tony Muchamuel, Maya Dajee, Deborah Swinarski, Monette Aujay, Mark K Bennett, PhD, Jinfu Yang, Evan Lewis, Guy Laidig, Christopher J. Molineaux, PhD

Blood (2008) 112 (11): 2765.

https://doi.org/10.1182/blood.V112.11.2765.2765

Published: 2008

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

Journal Articles

Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.

Francesco Parlati, Monette Aujay, Siv Lise Bedringaas, Susan Demo, Bjorn Gjertsen, Eileen Goldstein, Jing Jiang, Christopher Kirk, Guy Laidig, James Lorens, Yan Lu, David Micklem, Paulina Ruurs, Kevin Shenk, Catherine Sylvain, Congcong Sun, Tina Woo, Han-Jie Zhou, Mark Bennett

Blood (2007) 110 (11): 1599.

https://doi.org/10.1182/blood.V110.11.1599.1599

Published: 2007

NARROW

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia

Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.

Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.

PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only